INTRODUCTION

Employer-sponsored wellness programs have proliferated in the United States since the 1990s. Projections have estimated that the corporate wellness industry could exceed $12 billion US sometime in 2020 (Roberts & Fowler, 2017; Wolfe, 2018). In 2018, 82% of large firms and 53% of small employers in the United States offered a wellness program, with key health and wellness components, including nutrition, physical activity, stress reduction, and preventive services (Song & Baicker, 2019). Despite the high prevalence of employer-sponsored wellness programs (Roberts & Fowler, 2017),
the concept has no universally accepted definition. Generally-speaking, wellness programs offer employment-based activities to employees to promote healthy behaviors, prevent and/or manage disease. Congress encouraged wellness programs when it passed the Affordable Care Act (ACA; Patient Protection & Affordable Care Act, 2010), which sets statutory standards for two categories of wellness programs: “participatory” wellness programs and “health contingent” wellness programs (the latter of which may be either activity-only condition management or outcome-based). The ACA defines a “participatory” wellness program as one in which “none of the conditions for obtaining a reward under a wellness program is based on an individual satisfying a standard that is related to a health factor (or if a wellness program does not provide a reward)” [26 CFR § 54.9802-1(f)(ii); 29 CFR § 2590.702(f)(ii); and 45 CFR § 146.121(f)(ii)] and defines a “health contingent” wellness program as “a program that requires an individual to satisfy a standard related to a health factor to obtain a reward (or requires an individual to undertake more than a similarly situated individual based on a health factor in order to obtain the same reward)” [26 CFR § 54.9802-1(f)(iii); 29 CFR § 2590.702(f)(iii); and 45 CFR § 146.121(f)(iii)].

It has long been promised that employee wellness programs would provide health benefits and also reduce healthcare costs, but evidence for this is scant (Song & Baicker, 2019). An 18-month cluster randomized trial of 32,974 employees at 160 worksite sites run by Harvard Medical School and the National Bureau of Economic Research aimed to determine if corporate wellness programs improved employee health and reduced healthcare costs. Although the results showed an improvement in employee self-reported positive health behaviors, there was no significant change in healthcare spending, healthcare utilization, or clinical measurements of health for employees, and no significant impact on employment outcomes such as absenteeism and work performance (Song & Baicker, 2019).

Over the last decade, genomic medicine has been promoted as providing the ability to individualize care and improve health outcomes (Manolio et al., 2019). A major challenge to genomic medicine implementation has been the lack of evidence of clinical utility (net benefit of testing) and lack of reimbursement by insurers (Peterson et al., 2019). While privacy concerns remain an important consideration in any genetic service delivery setting, in the context of employer/employee relationships and access to genetic data, these privacy concerns are magnified (Song & Baicker, 2019). Recognizing these challenges, there has been increased interest in exploring the responsible integration of genetic technologies and genetic information in employer-sponsored health and wellness programs. In March 2019, the National Human Genome Research Institute (NHGRI) sponsored a “Genomics in Health and Wellness Meeting” to discuss the potential benefits and barriers to offering pre-emptive testing for genetic conditions in the workplace. Meeting recommendations included development of a framework for implementing and evaluating employee genetic testing, including assessment of outcomes of relevance to employers and employees such as impact on health status, productivity, and health care costs (Tamburro, 2019).

Proponents assert that genetic testing offered in this way (i.e., voluntary, health-related testing for employees, and their dependents with or without a personal or family history of genetic disease) might improve the identification of evidence-based and medically actionable risks, help participants be more actively engaged in their health and well-being, improve genetic and health literacy broadly, identify health risks earlier, and promote safer and more effective medication use. Knowledge of genetic risk could inform a variety of preventive measures, leading to the avoidance or mitigation of disease and associated costs. This possibility was anticipated by Congress when the Genetic Information Nondiscrimination Act (GINA; Genetic Information Nondiscrimination Act of 2008) was debated and passed more than a decade ago. GINA strictly forbids employers from obtaining or even requesting genetic information from employees (i.e., the statute includes a privacy mechanism as a means to preclude discriminatory uses of genetic information), but there is a statutory exception for employer-sponsored wellness programs that meet enumerated criteria (42 U.S.C.§, 2000ff-1). Nevertheless, integration of genetic technologies in employer-sponsored wellness programs has been and continues to be controversial. Scholarly discussion has focused on several controversial aspects of corporate wellness programs, for example, the coercive pressures that financial incentives for wellness program participation exert upon potential participants (thereby undermining voluntariness), the statutory interpretation and implementation (e.g., Blue, 2014; Madison, 2015; Rothstein, Roberts, & Guidotti, 2015; Sarata, DeBergh, & Staman, 2011); and the intensifying concerns about employee privacy (Ajunwa, Crawford, & Ford, 2016; Ajunwa, Crawford, & Schultz, 2017; Areheart & Roberts, 2019; Blue, 2014; Henninger, 2018; Kim, 2019; Madison, 2015; McIntyre, Bagley, Frakt, & Carroll, 2017; Roberts & Fowler, 2017; Rothstein et al., 2015; Sarata et al., 2011; Terry, 2018; Wolfe, 2018).

Much ink has been spilled regarding whether the statutory constraints imposed by the ACA, GINA, and the Americans with Disabilities Act (42 U.S.C§, 2000ff-1; Americans with Disabilities Act, 1990) are complementary or conflicting. This has been the subject of ongoing policy debates as well, including consideration of HR.1313 (American Society of Human Genetics, 2017; Condiles, 2019; Hudson & Pollitz, 2017; Maintaining Protections for Patients with Preexisting Conditions Act of, 2019, 2019; New York Times, 2017; NSGC Position Statement, 2017; Oliphant & Terry, 2016; Protect Act, 2019; Ray, 2017; The Preserving Employee Wellness Programs Act, 2017). Operationalizing these three
statutes (ADA, GINA, and ACA) necessitates a balancing or reconciliation of the nondiscrimination rights (and informational privacy rights) afforded under GINA and ADA with the promotion of health via wellness programs under ACA, and the Equal Employment Opportunity Commission (EEOC) is charged with this responsibility. When the EEOC issued its regulations, they were immediately and fiercely challenged. While voluntariness is a prerequisite to lawfulness of any wellness program as per GINA or ADA, what is “voluntary” is not defined by the statutes, calling into question whether financial incentives under ACA could be permissible when wellness programs implicate GINA or ADA (such as incorporating genetic information or testing). Initially, the EEOC had taken the position that incentives could not be tied to an employee’s disclosure of GINA- or ADA-protected information, but the EEOC reversed this position with issuance of its final rules in 2016 (EEOC, 2016a; EEOC, 2016b; EEOC, 2018a; EEOC, 2018b). Litigation ultimately led to the EEOC’s regulatory provisions on wellness programs being vacated (AARP v. EEOC & 292 F, 2017; AARP v. EEOC & 226 F, 2017; Equal Employment & Fed. Reg.65296-01, 2018; Equal Employment & Fed. Reg.65296-02, 2018; EEOC, 2019). While during litigation the EEOC had assured the D.C. District Court that replacement rules would be issued by October 2019 and while this item was on the EEOC’s regulatory agenda for fall 2019 with explicit expectation of proposed rules issuing by January 2020, no proposed text for interim or final rules has yet (as of 20 May 2020) been issued. While the statutory provisions and bulk of implementing regulatory provisions remain in place, regulatory uncertainty persists with regard to wellness programs integrating genetic information or testing components and contemplating incentives.

Thus, despite any potential health benefits that the integration of genetic services into employer-sponsored wellness programs might have, there is ample reason to examine the policies and practices of genetic testing products offered by vendors to employers. To better understand genetic services offered by corporate wellness program vendors, we undertook a landscape analysis of current vendor products and practices using information available publicly online.

2 | MATERIALS AND METHODS

To identify vendors offering corporate wellness programs with genetic services, a systematic search of vendors offering business-to-business (BTB) genetic testing as part of a corporate wellness program was conducted using the Google search engine. BTB corporate wellness vendors were defined as companies (i.e., vendors) that sell products (i.e., corporate wellness programs) directly to other businesses (i.e., employers). Search strings were identified from keywords listed in relevant academic research articles and news coverage that addressed topics on and related to genetic testing as a corporate wellness strategy. Sixteen (16) unique search strings were identified (Table 1). Webpages in the United States, written in English, and last updated no earlier than 1 January 2000 were automatically included in the search results using Google’s advanced search feature and filter tool. The first 30 uniform record locators (URLs) results were recorded for each search string and a total of 480 results were recorded for all 16 search strings used. These methods (use of Google and focusing the analysis on the first 30 URLs in the results) were selected based on a preliminary set of searches that were performed to determine a reasonable approach. The preliminary searches was performed using three search engines (Bing.com, Yahoo.com, and Google.com) and a single search string (“Corporate wellness program genetic testing”). The first 100 URLs from each search engine’s results were compared. Google outperformed the other two search engines in identifying the most vendors, and saturation was reached within 30 URLs of the results (i.e., reviewing URLs after the

| Unique search strings                          | Number of vendors identified |
|-----------------------------------------------|------------------------------|
| 1 Worksite wellness program genetic testing   | 1                            |
| 2 Organizational wellness genetic testing     | 6                            |
| 3 Corporate wellness genetic testing          | 8                            |
| 4 Workplace health promotion genetics         | 1                            |
| 5 Employee Wellness genetic screening         | 4                            |
| 6 Corporate wellness program genetic testing  | 6                            |
| 7 Employee precision health genetics          | 3                            |
| 8 Employee clinical genomics                  | 2                            |
| 9 Employer-sponsored wellness genetic testing | 3                            |
| 10 Worksite wellness program genetic testing  | 3                            |
| 11 Worksite health promotion programs genetic testing | 1                  |
| 12 Employer-based wellness genetic testing    | 3                            |
| 13 Wellness vendors genetic testing           | 1                            |
| 14 Genetic test & employee                    | 2                            |
| 15 Employer genetic testing                   | 2                            |
| 16 Weight loss corporate wellness genetic testing | 6                  |

The “unique search strings” column shows the search strings that were used for the Google search. The “number of vendors identified” column demonstrates the number of vendors that were identified in the Google results page with each search string.
30th search result was unlikely to yield any additional unique vendors). Each URL was reviewed to first identify vendors that appear to sell (not merely promote or advertise) a corporate wellness program to employers. Most of the URLs directed to news articles and commentary about corporate wellness programs, direct to consumer genetic testing, and direct to consumer wellness programs. The resulting vendors were further refined by only including those that offer genetic testing as a component of their corporate wellness program (which is some cases was the sole wellness offering). The systematic Google search was performed November 27 to 1 December 2019 (Figure 1).

Like methods used for landscape analyses of various sectors of the DTC industry (Wagner, Cooper, Sterling, & Royal, 2012), content analysis of the websites for each of the vendors identified in the systematic search was performed, and data collection for each vendor was started and completed on a single day (Table S1). Data were collected between 1 December 2019 and 9 December 2019, and each vendor’s website was analyzed independently. The data gathered about each vendor included the following variables: vendor characteristics (vendor name, unique search strings used to identify the vendor in the systematic Google.com search [Table 1], URL to the vendor corporate wellness page, foundation date, headquarter address, scientific advisory board, and number of genetic testing products listed on their website) (Table 2). Data collected on vendor policies included the privacy policy, the policies on sharing data with employers, third parties, employee users, and primary care physician (PCP), the Health Insurance Portability and Accountability Act (HIPAA; Health Information Portability & Accountability Act, 1996), mention of GINA, the terms and conditions, jurisdictional areas excluded, stated limitations, and stated risks of the corporate wellness program and the genetic testing products. Vendor marketing points of emphasis (such as improved employee job performance, employee health outcomes, and employer financial outcomes) were assessed from the language used on the vendors’ corporate wellness page. Finally, the characteristics of the genetic testing products on the vendors’ websites were also examined, including the DNA collection method, the type of insight the test provides, the number of variants detected, the method at which results are delivered, the availability and type of posttesting counseling, the type of results available to the end user, and identification of the product as a component of the corporate wellness package (Table 2).

FIGURE 1 Systematic search methodology is a funnel plot of the systematic search strategy used to identify (1) business-to-business vendors of, (2) corporate wellness programs, (3) offering genetic tests and/or services as part of the corporate wellness program.
| Category                              | Variable                        | Definition                                                                                                                                                                                                 | Data structure |
|---------------------------------------|---------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Vendor organizational characteristics  | Vendor name                     | Name of the vendor.                                                                                                                                                                                       | Verbatim text  |
|                                       | URL                             | Uniform Record Locator to the vendor’s corporate wellness page.                                                                                                                                            | Website address|
|                                       | Foundation date                 | Date the vendor founded the company.                                                                                                                                                                       | Date           |
|                                       | Headquarter address             | Location of the primary offices.                                                                                                                                                                          | Physical address|
|                                       | Executive leadership            | Name of Founder, President or Executive officer(s).                                                                                                                                                       | Name(s)        |
|                                       | Leadership contact information  | E-mail address of executive leadership.                                                                                                                                                                   | E-mail address |
|                                       | Marketing slogan                | Large or bold stand-alone text on the top 30% of the vendor’s landing page.                                                                                                                                | Verbatim text  |
|                                       | Laboratory accreditation        | Laboratory accreditation acronyms listed anywhere on vendor website.                                                                                                                                     | Verbatim text  |
|                                       | Affiliate companies             | Companies with products that integrate with or are a supplement to the genetic products apparently sold by the vendor.                                                                                     | Company name   |
|                                       | Endorsements                    | Does the vendor mention other organizations that use their products or service?                                                                                                                           | Yes/No         |
|                                       | Stated market size              | The vendor reported market size or products offered.                                                                                                                                                      | Verbatim text  |
|                                       | Scientific advisory board       | Did the vendor have a group of independent scientists that advise on the scientific and technical aspects of the vendor’s business?                                                               | Yes/No         |
|                                       | Vendor-authored white paper     | Did the vendor publish an authoritative report that informs the reader of an issue within their industry and presents their philosophy on the issue at hand?                                                      | Yes/No         |
|                                       | Number of genetic testing products | Summation of the genetic testing products apparently sold by the vendor.                                                                                                                              | Number         |
|                                       | Privacy policy                  | Did the vendor have a statement disclosing the methods at which the vendor gathers, uses, discloses, and manages the employee user’s data?                                                                | Yes/No         |
|                                       | Data sharing with employers verbatim | Text addressing the vendors policies on sharing employee user’s data with employers.                                                                                                                  | Verbatim text  |
|                                       | Data sharing with employers (Y/N/na) | Evaluation of vendor policy language on the issue of sharing employee user data with employers to determine if data is (Yes) or is not (No) shared with employers. If the vendor policy language is vague, the data is coded as not available (na). | Yes/No/Not available (na) |
|                                       | Data sharing with 3rd-party (verbatim) | Text addressing the vendors policies on sharing the employee user’s data with third parties.                                                                                                           | Verbatim text  |
|                                       | Data sharing with 3rd-party (Y/N/na) | Evaluation of vendor policy language on the issue of sharing employee user data with third parties to determine if data is (Yes) or is not (No) shared with third parties. If the vendor policy language is vague, the data is coded as not available (na). | Yes/No/Not available (na) |
|                                       | Data sharing with employee user PCP (verbatim) | Text addressing the vendors policies on sharing the employee user’s data with the employee users primary care physician.                                                                         | Verbatim text  |
|                                       | Data sharing with employee user PCP (Y/N/na) | Evaluation of vendor policy language on the issue of sharing employee user data with the employee users primary care physician (PCP) to determine if data is (Yes) or is not (No) shared with the PCP. If the vendor policy language is vague, the data is coded as not available (na). | Yes/No/Not available (na) |
|                                       | HIPAA mentioned                 | Did the vendor mention the Health Insurance Portability and Accountability Act (HIPAA) on their website?                                                                                                 | Yes/No         |
|                                       | GINA mentioned                  | Did the vendor mention the Genetic Information Nondiscrimination Act (GINA) on their website?                                                                                                            | Yes/No         |
| Category                                      | Variable                                      | Definition                                                                 | Data structure |
|----------------------------------------------|-----------------------------------------------|---------------------------------------------------------------------------|----------------|
| Terms and Conditions                         | Did the vendor have a statement disclosing the rights and responsibilities of any individual using the site? | Yes/No                                                                   |                |
| Jurisdictional areas excluded                | Identifies the physical locations that each vendor cannot conduct business.                          | Physical location                                                         |                |
| Law enforcement coordination                 | Did the vendor mention that they would use and/or disclose personal health information in order to comply with federal, state or local law enforcement or public health activities? | Yes/No                                                                   |                |
| Governing law provision                      | The location in which rules and laws will govern in the event of a legal issue.                   | Physical location                                                         |                |
| Scientific peer-reviewed articles cited      | Did the vendor cite scientific peer reviewed articles about corporate wellness programs or the genetic test? | Yes/No                                                                   |                |
| Stated limitations                           | Text addressing risks associated with the use of the website or products. No text addressing limitations were listed as “na.” | Verbatim text                                                             |                |
| Stated risks                                 | Text addressing limitations associated with the use of the website or products. No text addressing risks were listed as “na.” | Verbatim text                                                             |                |
| Vendor marketing points of emphasis          | Did the vendors mention phrases such as “increased participation in wellness program” on their corporate wellness page? | Yes/No                                                                   |                |
| Employee participation                       | Did vendors mention phrases such as “stress levels,” “emotional health,” and/or “happiness” on their corporate wellness page? | Yes/No                                                                   |                |
| Employee morale improvement                   | Did vendors mention phrases such as “keep top talent” and “company loyalty” on their corporate wellness page? | Yes/No                                                                   |                |
| Employee talent retention                     | Did the vendors mention phrases such as “employee productivity” on their corporate wellness page?    | Yes/No                                                                   |                |
| Employee job performance                     | Did the vendors mention phrases such as “disease prevention” on their corporate wellness page?       | Yes/No                                                                   |                |
| Disease prevention                           | Did the vendors mention phrases such as “employees exercise regularly” and “employees make healthier diet choices” on their corporate wellness page? | Yes/No                                                                   |                |
| Employee health outcomes                     | Did the vendors mention phrases such as mention phrases “improve overall health” and “improved medical outcomes” on their corporate wellness page? | Yes/No                                                                   |                |
| Employer financial outcomes                  | Did the vendors mention phrases such as “positive return on investment,” “reduce healthcare costs” and “improved bottom-line” on their corporate wellness page? | Yes/No                                                                   |                |
| Benefit of corporate wellness program         | Text of the business case for employers to purchase the corporate wellness program.                 | Verbatim text                                                             |                |
| Genetic testing product characteristics       | Name of the genetic test advertised or appearing to be sold on the vendor website.                  | Verbatim text                                                             |                |
| DNA collection method                         | Method at which user's DNA is collected for each test: Saliva (1), Cheek swab (2), Blood draw (3), Variable (4), Inquiry required (na). | 1,2,3,4, na                                                             |                |
| Individual ordering test                      | The individual that is able to order the genetic test from the vendor: Employee user (1), Employee User PCP (2), or medical professional affiliated with vendor (3), Inquiry required (na). | 1,2,3, na                                                             |                |
| Individual collecting the DNA                 | The individual that is able to collect the DNA that will be tested: Employee user (1), Employee Users PCP (2), or health professional affiliated with vendor (3), Inquiry required (na). | 1,2,3, na                                                             |                |
| Insight                                       | Categories that define each genetic test: Ancestry & Familial (1), Traits & Conditions (2), Nutrigenetics (3), Fitness (4), Pharmacogenomics (5), Pathogenic Variants (6). | 1,2,3,4,5,6,                                                            |                |
DTC prices (see Table S2). Data regarding all genetic tests that each vendor offers were collected to understand the full range of tests that had the potential to be part of the corporate wellness program. A subsequent check of the vendors’ websites on 30 January 2020 revealed that, while many websites updated content, only three vendors updated their content to specify the genetic tests and services involved in their corporate wellness program (footnotes Table 3 and Table S2). The vendor websites were searched to identify their policies on sharing individual or aggregated identified or de-identified data with employers, third parties, and employee user’s PCP; vague policy language was also identified and is defined as language used by the vendor that is inconclusive with regard to their policy on sharing employee user data with employers, third-parties, or employee user PCPs. Most of the vendors were vague about their stance on sharing employee data with employers (60%, n = 9), only two vendors (13%) explicitly stated that they would share employee data with employers and four vendors (27%) stated that employee data would not be shared with employers (Table 4). An example statement that employee data are shared with employers and third parties found on the Color website is “if your employer has provided or paid for (in whole or in part) the Test, you acknowledge and agree that your de-identified Results and [Personal and

| Category | Variable | Definition | Data structure |
|----------|----------|------------|---------------|
|          | Number of traits tested | The number of specific characteristics within an individual that will be evaluated in a given genetic test, if this information is not available, the data is coded as "na." | Number |
|          | Number of variants tested | The number of genetic variations from the reference genome that will be evaluated in an individual's unique DNA sequence. If the information is not available, the data is coded as "na." | Number |
|          | Number of genes | The number of genes that will be evaluated in a given genetic test. If the information is not available, the data is coded as "na." | Number |
|          | Health conditions evaluated | The specific health conditions mentioned on the product page that the genetic test will detect. If no health condition is applicable for the genetic test in question, the data is coded as "none," if the information on the specific health condition is not available, the data is coded as "na." | Verbatim text |
|          | Results delivery | The methods at which results from each genetic testing product are delivered to the user: paper report (1), mobile app (2), website interface (3), one-on-one consultation (4), email (5), and Inquiry required (na). | 1,2,3,4,5, na |
|          | Counseling | The method at which the user receives a consult with a learned health or genetic professional to discuss the results of the genetic test: Genetic counselor (1), Health coach/dietitian (2), pharmacogenomics consultant (3), Physician (4), no consultation (none), and inquiry required (na). | 1,2,3,4, none, na |
|          | Stated benefits of the test | Text addressing the benefits of the genetic test in question. Verbatim text |
|          | Stated limitations of the test | Text addressing the limitation(s) of the genetic test in question. If no limitation is listed, the data is coded as "na." Verbatim text |
|          | Stated risks of the test | Text addressing the risk(s) of the genetic test in question. If no risk is listed, the data is coded as "na." Verbatim text |
|          | Listed price of the genetic test. | Price (USD) of the genetic test listed on the website. International currencies were converted to USD using the Google Finance Morningstar currency converter. Genetic tests without price information are listed as "na." ($) |
|          | Type of data accessible to the end user | The type of genetic result that the individual providing the DNA will have access to be categorized as raw genetic data files (1), summary data (2), no data (3), or inquiry required (na). 1,2,3, na |
|          | Product promoted as part of a wellness package | Evaluate the individual product page and corporate wellness page to determine of the product in question is clearly stated as part of the corporate wellness program. Yes/No/na |

Note: The data structure column identifies the type of data that was collected for each variable and the type of code that will be included in the raw table (see Table S2).
Family Health Information] PFHI may be anonymized and/or aggregated and returned to your employer or its designee (e.g., plan administrator or pharmacy benefits manager) as a data analytics resource... We may disclose your [personally identifiable information] PI and PHI to others involved in your care, including healthcare providers...”. The results

**TABLE 3** Business-to-business corporate wellness vendors offering genetic tests as a component or the entirety of the corporate wellness program displays data about each business-to-business corporate wellness vendor, identified in the systematic google search, appearing to offer genetic test, and services in their corporate wellness program

| Vendor name | URL | Foundation date | Headquarter city, state, country | Genetic test insight(s) | No. of genetic tests |
|-------------|-----|----------------|---------------------------------|-------------------------|---------------------|
| AGS Healtha | https://www.ags-health.com/corporate-wellness-genetic-testing-program | 2012 | Scottsdale, AZ, USA | Traits & Conditions Nutrigenetics Pharmacogenomics | 4 |
| ArcPoint Labs | https://www.arcpointlabs.com/ | 2005 | Greenville, SC, USA | Ancestry & Familial Nutrigenetics Fitness | 5 |
| BDS Adminb | https://bdsadmin.com/employer/wellness-programs/ | 1993 | Mechanicsburg, PA, USA | Nutrigenetics Fitness | 1 |
| Caligenix | https://www.caligenix.com/corporate-wellness | 2015 | Los Angeles, CA, USA | Traits & Conditions Nutrigenetics Fitness | 3 |
| Cambiatib | https://www.cambiatia.com/corporate-wellness-programs/ | 2009 | Lafayette, CA, USA | Nutrigenetics | 1 |
| Colorc | https://www.color.com/benefits-2 | 2015 | Burlingame, CA, USA | Traits & Conditions Nutrigenetics Pharmacogenomics Pathogenic Variants | 3 |
| Dextafit | https://www.dexafit.com/how-it-works/corporate-wellness | 2011 | Dallas, TX, USA | Fitness | 3 |
| DNA Fit-Prenetics | https://www.dnafit.com/us/enterprise/ | 2013 | Orpington, Kent, England, United Kingdom | Traits & Conditions Nutrigenetics Fitness Pathogenic Variants | 4 |
| Dynamic DNA Labs | https://dynamicdnalabs.com/pages/corporate-partners | 2015 | Springfield, MO, USA | Ancestry & Familial Traits & Conditions Nutrigenetics Fitness Pharmacogenomics | 13 |
| Genomaxx Fitness | https://www.genomaxxfitness.com/corporate-wellness/ | 2016 | San Diego, CA, USA | Traits & Conditions Nutrigenetics Fitness | 3 |
| Genome Medicald | https://www.genomemedical.com/employers/ | 2016 | South San Francisco, CA, USA | Pathogenic Variants | 3 |
| GenoVive | https://www.genoviveusa.com/corporate-wellness-programs/ | 2008 | New Orleans, LA, USA | Nutrigenetics Fitness | 1 |
| Pathway Genomics | https://www.pathway.com/corporate-wellness/ | 2009 | San Diego, CA, USA | Traits & Conditions Nutrigenetics Fitness Pharmacogenomics | 14 |
| Precision Genetics | https://precisiongenetics.com/our-solutions/ | 2015 | Greenville, SC, USA | Pharmacogenomics | 1 |
| Silverberry Genomix | https://silverberrygenomix.com/corporate-wellness-program/ | 2017 | San Francisco, CA, USA | Traits & Conditions Nutrigenetics Fitness Pharmacogenomics Pathogenic Variants | 12 |
The “genetic test insight(s)” column represents the six insight categories that each genetic test are defined by: (1) “nutrigenetics,” (2) “fitness,” (3) “traits & conditions,” (4) “Pharmacogenomics,” (5) “ancestry & familial,” and (6) “pathogenic variants.”

The corporate wellness page was updated as of 19 January 2020 to include a product named “Health and Wellness” (see Table S2 [cell S41]).

BDS Admin does not have a separate product page detailing the genetic test that is offered as part of their wellness program. The corporate wellness page does provide a brief description of the genetic test offered and from this description, the test was given the insight categories of a Nutrigenetics and fitness genetic test. See Table S2 [cell AM13] for the product description.

Since completing the data collection for this study December 2019, the corporate wellness page was updated as of 14 January 2020 to include three products now listed on their corporate wellness page named “Cancer,” “Heart,” and “Medication” none of which were identified during data collection. See Table S2 [cell S80].

This vendor did not appear to sell genetic tests but offered genetic counseling services direct to consumers and employers. In December 2019, the business model was to provide genetic counseling based on three services groups listed on their website (Proactive Genetic exploration, Advanced Genetic Care and Family Variant Insight Program). The descriptions on the website indicated the insight category to be pathogenic variant testing. See Table S2 [cell M38-M40] for descriptions of the three types of genetic services. The corporate wellness page was updated as of 19 January 2020 to include the names of the three genetic services (see Table S2 [cells S38:S40]).

### Table 4 Data sharing policies of vendors of B2B corporate wellness programs represents the data sharing policies mentioned on each of the vendor websites.

| Data shared with employers | Data shared with 3rd-party | Data shared with employee user PCP | HIPAA mentioned |
|----------------------------|----------------------------|-----------------------------------|-----------------|
| % of vendors               | % of vendors               | % of vendors                       | % of vendors    |
|   Explicit Yes             |   Explicit No              | Vague language                     | Vague language |
| 13%                        | 13%                        | 60%                               | 66.7%           |
| 27%                        | 27%                        | Vague language                     | 60%             |
| 40%                        | 40%                        | 27%                               | 40%             |
| 33%                        | 33%                        | 66.7%                             | 40%             |
| 66.7%                      | 66.7%                      | 40%                               | 60%             |
| 4%                         | 4%                         | Vague language                     | 40%             |
| 6%                         | 6%                         | 10%                               | 60%             |
| 9%                         | 9%                         | 9%                                | 60%             |

Each page on the vendor website was searched to identify language that addressed policies on sharing individual or aggregated identified or de-identified employee data with employers, third parties, and employee primary care physicians. Each vendor webpage was also searched to identify if HIPAA is mentioned. The language used by vendors on each policy was placed into three categories (1) “explicit Yes” meaning the vendors language used clearly states that the employee data will be shared with employers, third-parties or employee PCP; (2) “explicit No” meaning the vendors language used clearly states that the employee data will not be shared with employers, third-parties or employee user PCPs; and (3) “vague language” means the language used by the vendor is inconclusive with regard to their policy on sharing employee user data with employers, third-parties, or employee user PCPs.

vendors policies about sharing employee data with third parties show that six vendors (40%) explicitly stated that employee data will be shared, four (27%) explicitly stated that employee data would not be shared, and five (33%) vendors are vague about their policies on sharing employee data with third parties (Table 4). An example statement affirming employee user data will be shared with third parties found on the GenoMaxx website is “GenoMaxx Fitness™ may disclose your PHI to other companies or individuals who need your PHI in order to provide specific services to us. These other entities, known as “business associates” must comply with the terms of a contract designed to ensure that they will maintain the privacy and security of the PHI we provide to them or which they create on our behalf…”. Most vendor policies on sharing employee data with the employee user's PCP are vague about this policy (66.7%, n = 10), although 27% (n = 4) explicitly stated they share employee data with the employee's PCP and 6.7% (n = 1) explicitly stated they do not share employee data with the employee user's PCP. An example policy, found on the Caligenex website, about sharing employee user data with the employee user's PCP is “Only your healthcare professional will be able to access your genetic test results through the Caligenix Portal… All genetic data is sent through a secure 256-bit encryption server…”. The vendor websites were also searched to identify whether they mentioned HIPAA, and only nine vendors (60%) did so on any of their website’s pages (Table 4).

The vendor websites were further examined to identify stated risks and limitations involved in activities such as using their website, ordering products, using products, sharing data, and understanding results. Less than half (46.7%, n = 7) of all vendors stated any limitations on their website. An example limitation found on GenoVive's website was "the information provided by GenoVive and contained in this website, including an individual's results of the GenoVive Nutrition and Fitness Genetic Test, is not intended to prevent, diagnose or treat any medical condition and should not replace the advice of a physician". Only six vendors (40%) mentioned risks on their website; an example risk found on the Pathway Genomics website was "despite the reasonable and appropriate efforts of you and Pathway, there is always some risk that an unauthorized third party will access without our systems or intercept transmissions of your information" (Table 5). Most limitation and risk statements were found on the vendor terms and conditions, privacy policy, or consent pages (data not shown).

The marketing points of emphasis on each vendor corporate wellness page was searched to identify trends in the advertised benefits of corporate wellness program with genetic testing. The majority (86.67%, n = 13) of vendors mentioned...
### TABLE 5

Variability in risks and limitations mentioned on vendor websites displays examples of risks and limitations listed on the vendor website.

| Vendor name   | Example of limitation                                                                                                                                      | URL to limitation                          | Example of risk                                                                                                           | URL to risk |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|------------|
| AGS Health    | “Newborn screening is another problem that arises with EHRs (Electronic Health Records)—and genetic data. Tests done at birth vary from state to state, but all states must screen for at least 21 disorders by law, and some states test for 30 or more. Currently, tests are limited to conditions for which childhood medical intervention is possible and may be beneficial.” |
|               |                                                                                                                                                    | https://www.ags-health.com/privacystatement-2017 | na                                                                                                                       | na         |
| ArcPoint Labs | “The contents of our website, including any risk estimates or other reports generated by the services (collectively, “Your Report”) and any other information, data, analyses, editorial content, images, audio and video clips, hyperlinks and references (collectively, “Content”), are for informational purposes only and are not intended to substitute for professional medical advice, diagnosis, or treatment nor are they intended to be interpreted as a recommendation for a particular treatment plan.” |
|               |                                                                                                                                                    | https://www.arcpointlabs.com/home-kits/terms-conditions/ | na                                                                                                                       | na         |
| BDS Admin     | na                                                                                                                                                      | na                                         | na                                                                                                                       | na         |
| Caligenix     | na                                                                                                                                                      | na                                         | na                                                                                                                       | na         |
| Cambiati      | na                                                                                                                                                      | na                                         | na                                                                                                                       | na         |
| Color         | “Limitations of the test: … However, this test may not detect every variant associated with disease risk, or every variant or allele that may impact how a person processes or responds to medications… Color implements several safeguards to avoid technical errors, but as with all medical tests, there is a chance of a false positive or a false negative result…. In addition, if you have certain rare biological conditions or have had certain bone marrow, kidney, liver or heart transplants, transfusions, or hematologic malignancies, these conditions may limit the accuracy or relevance of the results or prevent the Test from being completed.” |
|               |                                                                                                                                                    | https://www.color.com/informed-consent    | “The Test is a genetic test that may cause you to discover sensitive information about your health or disease risks, including risk for hereditary disorders other than the one for which you are testing, or for disorders that currently have no treatment. The US Genetic Information Nondiscrimination Act of 2008 (GINA) prohibits discrimination on the basis of genetic information with respect to health insurance and employment. However, certain exceptions apply, and we encourage you to review GINA and related laws and regulations. There are currently no US federal laws that prohibit discrimination in life insurance, disability insurance or long-term care insurance, which may be governed by state law. If you live outside of the US, depending on your country of residence, there may be significant differences in the laws and regulations governing the use and disclosure of genetic information…” |
|               |                                                                                                                                                    |                                            | https://www.color.com/informed-consent |
| Vendor name | Example of limitation | URL to limitation | Example of risk | URL to risk |
|-------------|----------------------|------------------|----------------|------------|
| Dexafit     | “DexaFit Disclaimer
DexaFit technicians do not provide diagnosis or treatment at DexaFit facilities. They only answer basic questions based on the data from your testing, then suggest you follow up with your referring physician or one of DexaFit's licensed medical practitioners for further interpretation and consultations.” | https://www.dexafit.com/plans-and-pricing-1 | na | na |
| DNAFit-Prenetics | na | na | “Sharing Self-Reported Information through surveys, or other features on Our Site, is voluntary and done at your sole risk. DNAFit cannot take responsibility for Information that you release or that you request us to release publicly.” | https://www.dnafit.com/us/legals/privacy.asp |
| DynamicDNA Labs | na | na | “We are not responsible if information made available on this site is not accurate, complete or current. The material on this site is provided for general information only and should not be relied upon or used as the sole basis for making decisions without consulting primary, more accurate, more complete or more timely sources of information. Any reliance on the material on this site is at your own risk... Any use by you of optional tools offered through the site is entirely at your own risk and discretion and you should ensure that you are familiar with and approve of the terms on which tools are provided by the relevant third-party provider(s).” | https://dynamicedna.com/pages/legal |
| GenoMaxx Fitness | “4.2) Genetic research is not comprehensive...4.3) The laboratory may not be able to process your sample...4.4) The laboratory process may result in errors...4.5) We may not be able to present you with a full complement of results. In rare cases, despite our best efforts, it may not be possible to obtain an unambiguous result for some DNA variations (SNPs) due to biological or technical complications. This means that a result cannot be called clearly...4.8) The GenoMaxx Fitness™ product range is intended for informational and educational use only and is not intended to be used for medical advice or diagnosis or treatment.” | https://www.genomaxxfitness.com/terms-and-conditions/ | “4.6) Your Personal Information may be anonymised and used for research and development (R&D) purposes to contribute knowledge to the field and further improve our Products...4.7) Genetic Data you share with others could have social, legal or economic implications.
Use of genetic test results by employers in pre-employment medical checks is restricted in the UK by the Equality Act 2010, and in the US by the 2008 Genetic Information Nondiscrimination Act (GINA), which makes genetic discrimination illegal and addresses discrimination in health insurance and employment practices. However, as of yet, this protection does not explicitly cover life or disability insurance providers as these products are considered as more discretionary than health insurance.” | https://www.genomaxxfitness.com/terms-and-conditions/ |
| Vendor name       | Example of limitation                                                                 | URL to limitation                                                                 | Example of risk                                                                 | URL to risk    |
|-------------------|----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------|
| Genome            | na                                                                                     | na                                                                                | na                                                                              | na            |
| Medical GenoVive  | “The information provided by GenoVive and contained in this website, including an individual’s results of the GenoVive Nutrition and Fitness Genetic Test, is not intended to prevent, diagnose or treat any medical condition and should not replace the advice of a physician.” | https://www.genoviveusa.com/1126-2/                                              | na                                                        | na            |
| Pathway Genomics  | na                                                                                     | na                                                                                | “Despite the reasonable and appropriate efforts of you and Pathway, there is always some risk that an unauthorized third party will access without permission our systems or intercept transmissions of your information.” | https://www.pathway.com/privacy-statement/  |
| Precision Genetics| na                                                                                     | na                                                                                | Na                                                                              | na            |
| Silverberry Genomix | “Silverberry Statement of Limitations…DNA-based predisposition is NOT a diagnosis of a disease or condition. Predisposition risk or likelihood is a statistical measure based on the latest advances in genomics science and is provided as an additional layer of information for wellness decision-making. Silverberry recommendations fall within established non-medical guidelines for wellbeing and do not constitute medical advice. Consult with your Physician before making any major changes to your wellness or health choices.” | https://silverberrygenomix.com/our-science/                                     | “Potential Issues and Risks Keep in mind that the results may change how you feel, and there is a chance that some questions will make you uncomfortable. You can choose to not answer…Depending on the package you select, your results can reflect your health risks, fitness potentials, or predisposed personality traits. These could lead to many different emotions. We recommend that you discuss your results with a physician or other certified healthcare professionals before making any major changes to your routines.” | https://silverberrygenomix.com/consent |

**Percent with stated limitations or risks**: 46.7% – 40%

**Number of vendors**: 7 – 6

*Note: The columns titled “example of limitation” and “example of risks” contains verbatim text from the vendor website containing vendor disclosed risks and limitations. The column titled “URL to limitation” and “URL to risks” contains the web address where the example limitation or risk statement was first identified. The “na” indicates that the data is not available.*
employer financial outcomes as a benefit to purchasing their corporate wellness program. Employee health outcomes, employee job performance, and employee behavior change were frequently referenced by vendors (73.33% (n = 11), 66.67% (n = 10), and 60% (n = 9), respectively) as benefits to purchasing their corporate wellness program. Vendors also promoted their corporate wellness programs’ ability to improve employee morale (46.67%, n = 7), prevent disease among employees (33.33%, n = 5), and to retain employee talent (26.67%, n = 4). The least number of vendors (20%, n = 3) mentioned employee participation in the corporate wellness program as a reason for employers to purchase their corporate wellness program (Figure 2).

To determine the types of genetic tests that appear to be sold in the corporate wellness market, all genetic tests on the vendor websites were categorized by six insights: Nutrigenetics, fitness, traits & conditions, Pharmacogenomics, ancestry & familial, and pathogenic variant testing. A total of 71 genetic tests were identified across the 15 BTB corporate wellness vendors. Nutrigenetic testing category that identifies genetic variants associated with an individual’s differential responses to nutrition represented 28% (n = 20) of all genetic tests on the vendors websites and fitness genetic tests that identifies genetic variants in genes associated with body weight, differential responses to exercise, and variants associated with muscle mass and recovery also represented 28% (n = 20) of genetic tests on the vendors websites (Figure 3). The traits & conditions tests which identifies genetic variants implicated in an individual’s skin health, personality, food aversions, and allergies represented 24% (n = 17) of all genetic tests on the vendors websites. Pharmacogenomic tests which identifies an individual’s differential responses to pharmaceutical drugs and drug doses represented 21% (n = 15) of tests that appear to be sold by corporate wellness vendors. Pathogenic variant testing that detects genetic variants associated with the predisposition to inherited or sporadic diseases such as cancers (i.e., uterine, breast, ovarian, melanoma, pancreatic, stomach, and prostate), inherited heart disease (i.e., cardiomyopathy, arrhythmia, arteriopathy, and familial hypercholesterolemia), the American College of Obstetricians and Gynecologists (ACOG) recommended conditions (i.e., sickle cell disease, cystic fibrosis, and beta-thalassemia), and the Ashkenazi Jewish conditions (i.e., Bloom syndrome, mucolipidosis IV, and factor XI deficiency) represented 15.5% (n = 11) of all genetic tests that appeared to be sold on the corporate wellness vendors websites. The ancestry & familial tests that
detects familial relationships represented 13% (n = 9) of all genetic test offered among the BTB corporate wellness vendors (Figure 3).

The product page for each genetic test was evaluated to determine if a consultation with a physician, medical geneticist, genetic counselor, or health coach was available for individuals to discuss their test results and any recommended changes to their diet, exercise, medications, or health care. AGS Health, Caligenix, Cambiati, Color, DNA Fit, Dynamic DNA Labs, Genome Medical, and Pathway Genomics were
the only 8 vendors (53%) out of the 15 vendors identified that included health or genetic consultations as part of any genetic test or genetic service offered on their websites (Figure 4a). To identify health-related genetic testing products that include consultations, we excluded ancestry and familial testing from the analysis because we do not expect consultation to be offered with these tests; therefore, the denominator was reduced from 71 total tests to 62 health-related tests. Notably, 61% (n = 38) of all 62 health-related genetic tests in the BTB corporate wellness market did not offer any associated health-related consultation (Figure 4b). A consult with a health coach was included in 18% (n = 11) of the 62 tests, a pharmacogenomics consult was included in only 13% (n = 8) of the 62 tests, and a consultation with a physician was included in 13% (n = 8) of the 62 tests offered among the BTB corporate wellness vendors identified. Finally, products that offered genetic counseling represented only 10% (n = 6) of the 62 health-related genetic tests in the BTB corporate wellness market (Figure 4b). A total of 11 pathogenic variant tests were identified, and only 54.5% (n = 6) offered health or
-genetic consultations. Fifteen pharmacogenomics tests were identified, and only 53% (n = 8) offered posttesting health consultations (Figure 5). The traits & conditions, fitness, and Nutrigenetics test insight categories have a total of 17, 20 and 20 tests identified, respectively; however, only 35% (n = 6), 30% (n = 6), and 15% (n = 3), respectively, offered health and genetic consultations. As expected, none of the nine (9) tests in the ancestry & familial insight category offered health or genetic consultations (Figure 5).

The product page for each genetic test was evaluated to determine the method by which individuals received their genetic test results. Five categories of result reporting were identified among all 71 products apparently sold by the BTB corporate wellness vendors: (a) genetic results accessible through the vendor website or a third-party website contracted with the vendors; (b) genetic test results available through a mobile device like a phone or tablet; (c) genetic results available through a one-on-one consultation with a health professional; (d) genetic results available to print; or (e) genetic results available through email (Table 2). Products that are not clear about the method at which results are reported are indicated as “inquiry required.” Most of the product pages mention results are reported through a website 83% (n = 59) or through a mobile app 51% (n = 36). Select products delivered results through a one-on-one consultation 22.5% (n = 16), a paper report 22.5% (n = 16), and/or e-mail 7% (n = 5). Many of the product pages (11%, n = 8) were not clear about the method at which results were reported to the individual (Figure 6).

4 | DISCUSSION

The RAND Corporation identified five attributes for successful corporate wellness programs: (a) develop effective communication strategies about the wellness program to employees, (b) provide opportunities for employees to engage in the wellness program, (c) engage leadership and promote a culture of wellness, (d) use existing resources, and (e) continue to evaluate and improve the wellness program (Mattke, 2013). These five attributes were not readily apparent from the websites of the 15 BTB corporate wellness vendors appearing to incorporate genetic testing into their wellness program that we systematically identified. While broad generalizations should be avoided (as what these vendors are doing could be distinct from what their online information suggests) and while further research is needed to understand vendor and employer behavior when initiating an employer-sponsored wellness program involving genetic testing and services, a few observations are appropriate.

Effective communication and outreach strategies in the form of genetic and health counseling is apparent among only 53% of corporate wellness vendors analyzed. Learned professionals are needed to communicate the limitations and risks of specific genetic tests and the implications of any identified pathogenic variants. It is a noteworthy gap that some vendors do not offer the critical benefit of health and genetic counseling to employee-participants.

Most wellness vendors identified in the systematic search allow for the individuals to provide DNA samples at home which is a significant convenience compared with a mandatory doctor’s visit. A major accessibility concern emergent from our observations was that individuals’ access to genetic test results was biased toward users of website and mobile applications, leaving few opportunities for individuals with no access to or limited proficiencies with computers or advanced mobile technologies to participate fully in the program. Known age, race, and economic disparities in the distribution of technologies and information is especially concerning when it comes to genetic information because of the potentially life-changing impact of a pathogenic variant and a pharmacogenomic result. Further efforts are needed to understand and close the “digital divide” and its impacts on uptake of genetic testing services.

Understanding GINA and HIPAA compliance is important for corporate decision-making when selecting vendors for wellness programs. Corporate leadership might be inclined to implement wellness programs with genetic testing into their organization’s benefits package if wellness program vendors were transparent about their efforts to ensure compliance with GINA and HIPAA. Given the regulatory uncertainty surrounding the use of financial incentives for employer-sponsored wellness programs involving genetics and the continued confusion and limited awareness regarding what employer obligations under GINA and related state laws are in this area, it is incumbent on vendors of corporate wellness programs involving genomics to be aware and able to guide their prospective business customers. Our review of online information provided by vendors revealed very few even mentioning HIPAA and GINA among their online materials, which is a potential red flag that the legal and policy issues are not given adequate attention. Furthermore, in the vendor-stated risks and limitations of the corporate wellness program, standard disclaimer language was used to absolve vendors from both regulatory oversight and liability. Best practices for this industry should include, at a minimum, disclosures by the vendors detailing how their program aligns with GINA and relevant state laws protecting employee privacy and nondiscrimination rights. Transparency regarding what (if any) data access is provided by the vendors to employers and what (if any) data sharing with third parties is occurring are particularly important details given a variety of intertwined legal requirements (e.g., GINA’s mandate that employers not have access to anything more than aggregated, de-identified information; the ADA’s prohibition against
employers compelling employees to agree to data transfers to third parties; but HIPAA’s allowance for data sharing with “business associates”) and growing public discontent over data privacy and governance.

Well-established corporate wellness program vendors, such as Wellness Corporate Solutions, Virgin Pulse, and Provant Health Solutions (Aditi, 2019) were not among those vendors identified as offering genetic testing services, highlighting genetic testing in wellness as a niche business proposition. That mainstream wellness programs have yet to incorporate genetic testing could be due to several factors, including but not limited to the lack of empirical evidence of positive return on investment and the actual or perceived regulatory constraints. Vendors did not report their own programmatic successes or provide evidence to substantiate their claims that genetic testing in corporate wellness improves health or reduces health-care costs. The omission of this information further frustrates attempts by employee-rights advocates to evaluate whether vendors are offering products and services that are adequately supported by scientific evidence, or alternatively, offering nothing more than a test with unproven benefits and the potential for clinical harms. If the observed trends persist, those vendors eager to push genetic testing in corporate wellness may undermine broader efforts to promote evidence-based, medically actionable genetic testing for unselected individuals in the U.S. workforce.

Another profoundly troubling finding is that at the time data collection was completed (9 December 2019), none of the vendors described the details of the genetic tests and services offered specifically as part of their corporate wellness program. All understanding about options available to employers is entirely speculative because the vendors’ DTC offerings might or might not align with the BTB wellness program offerings. As of 30 January 2020, only 3 of the 15 vendor websites have specified the genetic tests that are offered in their corporate wellness program. Although a small number with substantial room for improvement, this indicates a positive shift toward improved transparency among corporate wellness program vendors. Further research is needed to understand vendor and employer behavior when initiating and participating in an employer-sponsored wellness program involving genetic testing and services.

As scholars such as Anya Prince (Prince, 2015) have rightly noted, the provision of genetic information is not itself prevention but is dependent upon subsequent actions based on that information that are themselves influenced by contextual conditions (such as financial opportunity). If genetic testing and services are to offer opportunities for wellness programs to demonstrate effectiveness in improved health and well-being for participants and reduced health care costs, we must encourage vendors of employer-sponsored wellness programs to consistently contribute standardized performance data so that we can collectively evaluate if genetic testing in corporate wellness adds value or if, as scholars have already commented (Manolio et al., 2019, at 80) “[i]t is time...to rethink [this] enthusiasm for the wellness movement.”

ACKNOWLEDGMENTS
This research was funded by the National Human Genome Research Institute (NHGRI) Award No. R01HG009694-03S1 to Vanderbilt University (as prime) and Geisinger Clinic as a subaward. The content of this article is solely the authors’ responsibility and might not represent the views of the authors’ funding sources, employers, or any other person or entity. The protocol for this research was submitted to the Geisinger Institutional Review Board and determined not to be human subjects research (IRB #2019-1117) on November 26, 2019.

CONFLICT OF INTERESTS
This research was funded by the National Human Genome Research Institute (NHGRI) Award No. R01HG009694-03S1. Dr. Peterson is a consultant for Color Genomics (http://www.color.com). The authors declare no other potential conflicts of interest with the information presented in this manuscript and specifically declare no interests with any of the vendors identified in this manuscript.

AUTHORS’ CONTRIBUTION
W.M. conceived the idea, W.M., J.W., M.W., and P.D. developed and designed the study methodology, W.M collected, and analyzed the data, W.M., J.W., M.W., and P.D. interpreted the data., W.M and J.W drafted the manuscript, W.M., J.W., P.D., M.W., L.W., and J.P. provided editorial assistance and approved the final version of the manuscript.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Whitney S. McDonald https://orcid.org/0000-0001-9600-3158
Jennifer K. Wagner https://orcid.org/0000-0002-2278-0306
Patricia A. Deverka https://orcid.org/0000-0002-1777-4286
Marc S. Williams https://orcid.org/0000-0001-6165-8701

REFERENCES
42 U.S.C. 2000ff-1. Sec. 202(b)(2). (2010, November 9).
Aarp v. Eeoc, 292 f. Supp. 3d at 240 (d.d.c. 2017).
Aditi, N. G. (2019). Corporate wellness market in the US - industry outlook and forecast 2019-2024. Retrieved from https://www.reportbuyer.com/product/5796152/corporate-wellness-marke
AJUNWA, I., CRAWFORD, K., & FORD, J. S. (2016). Health and big data: An ethical framework for health information collection by corporate wellness programs. The Journal of Law, Medicine & Ethics, 44, 474–480.

AJUNWA, I., CRAWFORD, K., & SCHULTZ, J. (2017). Limitless worker surveillance. California Law Review, 105, 735–776.

American Association of Retired Persons vs. Equal employment opportunity commission. 226 F. Supp. 3d §7 (D. D.C., 2017).

American Association of Retired Persons vs. Equal employment opportunity commission. (2018) Equal Employment Opportunity Commission, 292 F. Supp. 3d §238 (D. D.C.).

American Society of Human Genetics. (2017). ASHG Opposes H.R.1313, the Preserving Employee Wellness Programs Act Bill Would Undermine Genetic Privacy Protections [Press release]. Retrieved from https://www.ashg.org/press/201703-HR1313.html

Americans with Disabilities Act of 1990 (ADA). (1990). Pub. L. 101–336, 104 Stat.327. Amended by ADA Amendments Act of 2008, Pub. L. 110–233, 122 Stat. 3553 (2008).

Areheart, B. A., & Roberts, J. L. (2019). GINA, big data, and the future of employee privacy. Yale Law Journal, 128, 710–740.

Blue, E. P. (2014). Wellness programs, the ADA, and GINA: framing the conflict. Hofstra Labor & Employment Law Journal, 31, 367–385.

Condiles, A. (2019). How voluntary is voluntary: designing wellness programs to fit the participant. Appalachian Journal of Law, 18, 1–24.

Equal employment opportunity commission, proposed rule: genetic information nondiscrimination act of 2008, 80 fed. Reg. 66853-01 (October 30, 2015).

Equal employment opportunity commission (EEOC). (2016a) Final rule: regulations under the americans with disabilities act, 81 fed. Reg. 31126–01.

Equal employment opportunity commission. (2016b) Final rule: genetic information nondiscrimination act, 81 fed. Reg. 31143–01.

Equal Employment Opportunity Commission. (2018a). Final Rule: Removal of Final ADA Wellness Rule Vacated by Court, 83 Fed. Reg. 65296-01.

Equal Employment Opportunity Commission. (2018b). Final Rule: Removal of Final GINA Wellness Rule Vacated by Court, 83 Fed. Reg. 65296-02.

Equal employment opportunity commission regulations. Retrieved from https://www.eeoc.gov/eeoc-regulations

Equal employment opportunity commission statement of regulatory and deregulatory priorities. Retrieved from https://www.reginfo.gov/public/do/eagen domain?option=operation_get_agency_rule_list&currentpub =true&agencycd=3046&image58.x=55&image58.y=18

Genetic Information Nondiscrimination Act of 2008 (GINA). (2008). Pub. L. 110–233, 122 Stat. 881.

Health Information Portability and Accountability Act (HIPAA) (1996). Pub. L. 104–191, 110 Stat. 1936.

Henniger, J. (2018). Wearable technology and employer wellness programs: gaps and solutions. Ohio State Business Law Journal, 12, 197–218.

Hudson, K. L., & Pollitz, K. (2017). Undermining genetic privacy? employee wellness programs and the law. New England Journal of Medicine, 377, 1–3.

Kim, P. T. (2019). Data mining and the challenges of protecting employee privacy under U.S. Law. Comparative Labor Law & Policy Journal, 40, 405–419.

Madison, K. (2015). Employer wellness incentives, the Aca, and the ADA: Reconciling policy objectives. Willamette Law Review, 51, 407–457.

Maintaining Protections for Patients with Preexisting Conditions Act of 2019, H.R. 4159, 116th Congress. (2019). (Rep. Denver Riggleman, R-VA-5)

Manolio, T. A., Rowley, R., Williams, M. S., Roden, D. M., Ginsburg, G. S., Bult, C., … Green, E. D. (2019). Opportunities, resources, and techniques for implementing genomics in clinical care. Lancet, 394, 511–520.

Mattice, S., Liu, H., Caloyeras, J., Huang, C. Y., Van Busum, K. R., Khodyakov, D., & Shier, V. (2013). Workplace wellness programs study: Final report. Rand Health Quarterly, 3(2), 7. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/28083294

McIntyre, A., Bagley, N., Frakt, A., & Carroll, A. (2017). The dubious empirical and legal foundations of workplace wellness programs. Health Matrix, 27, 59–80.

New York Times. (2017). How healthy are you? G.O.P. Bill would help employers find out. Retrieved from https://www.nytimes.com/2017/03/10/health/workplace-wellness-programs-health-h-genetic-data.html

NSGC Position Statement (2017). Workplace Wellness Programs. Retrieved from https://www.nsgc.org/pbl/testblogaid=971

Oliphant, E. N., & Terry, S. F. (2016). GINA and ADA: new rule seriously dents previous protections. Genetic Testing and Molecular Biomarkers, 20(7), 339–340.

Patient Protection and Affordable Care Act (ACA). (2010). Pub. L. 111–148, 124 Stat. 119.

Peterson, J. F., Roden, D. M., Orlando, L. A., Ramirez, A. H., Menagh, G. A., & Williams, M. S. (2019). Building evidence and measuring clinical outcomes for genomic medicine. The Lancet, 394(10198), 604–610.

Prince, A. E. R. (2015). Prevention for those who can pay: insurance reimbursement of genetic-based prevention interventions in the liminal state between health and disease. Journal of Law and the Biosciences, 2(2), 365–395.

Protect Act, S. 1125, 116th Congress. (2019). (Sen. Thom Tillis, R-NC).

Ray, T. (2017). Employee wellness bill could stifle genetics research in age of big-data studies, GenomeWeb. Retrieved from https://www.genomeweb.com/policy-legislation/employee-wellness-bill-could-stifle-genetics-research-age-big-data-studies#Xdl2y3MwUE

Roberts, J. L., & Fowler, L. R. (2017). How assuming autonomy may undermine wellness programs. Health Matrix, 27, 101–123.

Rothstein, M. A., Roberts, J. L., & Guidotti, T. L. (2015). Limiting occupational medical evaluations under the americans with disabilities act and the genetic information nondiscrimination act. American Journal of Law and Medicine, 41, 523–567.

Sarata, A. K., DeBergh, J. V., & Staman, J. (2011). The genetic information nondiscrimination act of 2008 and the patient protection and affordable care act of 2010: overview and legal analysis of potential interactions. Congressional Research Service (R41314). Retrieved from https://www.govinfo.gov/Pages/PolicyEthics/GeneticDiscrimination/CRS_GINA_and_ACA.pdf

Song, Z., & Baicker, K. (2019). Effect of a workplace wellness program on employee health and economic outcomes. JAMA, 321(15), 1491.

Tamburro, C. (2019). Executive Summary. In: MD: National Human Genome Research Institute. Retrieved from https://www.genome.gov/
Terry, N. P. (2018). Appification, AI, and healthcare’s new iron triangle. *Journal of Health Care Law & Policy, 20*, 117–181.

The Preserving Employee Wellness Programs Act (115th Congress), H.R.1313, 115th Cong., (2017) (Rep. Virginia Foxx, R-NC-5).

Wagner, J. K., Cooper, J. D., Sterling, R., & Royal, C. D. (2012). Tilting at windmills no longer: A data driven discussion of DTC DNA ancestry tests. *Genetics in Medicine, 14*(6), 586–593.

Wolfe, J. (2018). Coerced into health: workplace wellness programs and their threat to genetic privacy. *Minnesota Law Review, 103*, 1089–1133.

How to cite this article: McDonald WS, Wagner JK, Deverka PA, Woods LA, Peterson JF, Williams MS. Genetic testing and employer-sponsored wellness programs: An overview of current vendors, products, and practices. *Mol Genet Genomic Med.* 2020;00:e1414. [https://doi.org/10.1002/mgg3.1414](https://doi.org/10.1002/mgg3.1414)